NCT01505647View on ClinicalTrials.gov

Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1)

PHASE3CompletedINTERVENTIONAL

Enrollment

498

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

November 30, 2012

Conditions

Herpes ZosterShingles

Interventions

BIOLOGICAL

Zoster Vaccine, Live (AMP)

One approximately 0.65-mL injection subcutaneously on Day 1

BIOLOGICAL

Zoster Vaccine, Live

One approximately 0.65-mL injection subcutaneously on Day 1

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01505647 - Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1) | Biotech Hunter | Biotech Hunter